Farm Progress is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

New Locations for Base of Ear Administration Approved for EXCEDE

New Locations for Base of Ear Administration Approved for EXCEDE
Two new techniques will allow cattle producers to decide which is best for their herd.

Pfizer Animal Health announces two new base of ear locations for subcutaneous administration have been approved in beef and dairy cattle for EXCEDE (ceftiofur crystalline free acid) Sterile Suspension. These new techniques are in addition to the existing base of ear "toward the opposite eye" approved route of administration for all cattle, as well as the "middle third of the ear," which is approved in beef cattle and dairy heifers less than 20 months of age.

Two new techniques for EXCEDE administration will allow cattle producers to decide which is best for their herd.

The two new techniques are a rostral direction, or toward the eye on the same side of the head, and a ventral administration, which is similar to a normal subcutaneous injection given at the base of the ear. The graphics below detail the two new techniques.

New Locations for Base of Ear Administration Approved for EXCEDE

"I think veterinarians and producers will find the newly approved injection techniques to be more convenient than what we've previously had available for EXCEDE," says Doug Hammon, DVM, Ph.D., senior manager, Cattle Technical Services, Pfizer Animal Health. "Producers should work with their veterinarian to determine which base of ear injection technique for EXCEDE works best with their herd management protocols."

All approved administration locations provide the same 13-day meat withdrawal time and zero milk withholding following the last dose. EXCEDE also supports the tenets of Beef Quality Assurance and is backed by the Residue Free Guarantee.

To learn more about EXCEDE and the newly approved base of ear administration locations, visit

Safety Information

Important Safety Information: As with all drugs, the use of EXCEDE is contraindicated in animals with known allergy to ceftiofur or to the ß-lactam group (penicillins and cephalosporins) of antimicrobials. Though safe in cattle when properly administered, inadvertent intra-arterial injection is possible and fatal. EXCEDE has a pre-slaughter withdrawal time of 13 days following the last dose in cattle. Do not use in calves to be processed for veal.

Prescribing Information

*Residue Free Guarantee: If you use a Pfizer Animal Health-branded ceftiofur product according to label indications, and experience a violative ceftiofur milk or meat residue, Pfizer Animal Health will compensate you for the beef market value of the animal or purchase the tanker of milk at fair market value. You must purchase the product from a Pfizer Animal Health-approved supplier, use the product according to label indications, have documentation of the product purchase and treatment records, and have conducted training on appropriate use to ensure proper dose and route of administration of the product. Extra-label use as prescribed by a veterinarian is excluded from the guarantee. If you experience a ceftiofur residue violation after following label indications and the above steps, contact Pfizer Animal Health Veterinary Medical Information and Product Support at 855-424-7349 to report the situation.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.